Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Biotech
Royalty bestows Zenas with $300M for autoimmune approval push
Royalty is paying Zenas $75 million upfront, with similar payments coming if obexelimab succeeds in phase 3 and secures FDA approval.
Darren Incorvaia
Sep 2, 2025 11:07am
Fierce Pharma
Vor Bio's surprise $4B revival deal splits investor reactions
Jun 26, 2025 10:55am
Merck KGaA sheds light on failed portion of phase 2 lupus trial
Jun 12, 2025 9:41am
After setback, Merck KGaA shows data justifying lupus ph. 3 push
May 21, 2025 9:50am
Charles River and Valo pact nets preclinical lupus asset
Mar 26, 2025 6:30am
Merck KGaA fails lupus trial arm, plans further development
Mar 6, 2025 7:25am
